Cardiometabolic Toxicities of Targeted Cancer Treatments

A special issue of Toxics (ISSN 2305-6304). This special issue belongs to the section "Human Toxicology and Epidemiology".

Deadline for manuscript submissions: closed (20 December 2023) | Viewed by 163

Special Issue Editors

Department of Pharmacy, University of Patras, 26504 Patras, Greece
Interests: biochemistry; molecular biology; immunology; molecular pharmacology
Special Issues, Collections and Topics in MDPI journals
Department of Pharmacy, University of Patras, 26504 Patras, Greece
Interests: preclinical and clinical drug evaluation; molecular targets of drug action; precision therapeutics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We invite you to contribute to the Special Issue of Toxics, entitled “Cardiometabolic Toxicities of Targeted Cancer Treatments" aiming to attract and highlight state-of-the-art and timely research submissions addressing the field of cardiometabolic toxicities from targeted cancer therapies.

Each year, more than a million people are diagnosed with cancer worldwide, and some are at risk of treatment-related toxicities. Several targeted therapies are commonly used across various cancer types, including anti-HER2, tyrosine kinase inhibitors, immune checkpoint inhibitors, proteasome inhibitors, etc. A targeted approach often exploits the differences between cancer and non-cancer cells; however, overlap in signaling pathways necessary for maintaining function and survival in multiple cell types has resulted in systemic toxicities. Although immune checkpoint inhibitors are better tolerated than conventional chemotherapy, their use is associated with a peculiar toxicity profile related to the enhancement of the immune response, affecting several organs. Cardiovascular toxicity can develop with these types of molecularly targeted therapies, which can cause serious side effects, including left ventricular dysfunction, hyper- or hypotension, thromboembolism, ischemia, cardiomyopathy, heart failure, arrhythmias, vascular disease, hyperlipidemia, etc. Moreover, up to 10% of immune-related adverse events involve the endocrine and metabolic system, mainly affecting the thyroid organ and leading to thyroid disorders. Addressing cardiovascular risk at baseline, before initiating therapy, during cancer treatment, and in the survivorship period is imperative. A deeper understanding of endocrine toxicities is a critical goal for both oncologists and endocrinologists/pathologists.

Submitted studies may include but are not limited to original articles, expert reviews, short communications, opinion letters, and any clinical studies targeting to explore better and highlight the in vitro or in vivo toxicities encountered by targeted cancer treatment. This Special Issue will serve as a platform for cutting-edge articles and an updated forum for scientists to exchange knowledge and ideas.

Dr. George Lagoumintzis
Prof. Dr. Stavros Topouzis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiometabolic
  • cytotoxicities
  • targeted therapy
  • cancer
  • molecular pharmacology

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop